AGT has developed, tested and banked thousands of Lentiviral vectors with different characteristics. For many diseases, it is possible to adapt one of AGT’s existing vectors to the specific needs of a new target disease. Because AGT’s vector designs are easily re-usable across diseases, the time to develop a new drug candidate can be measured in weeks instead of years, providing extremely quick proof of concept and allowing very rapid go/no-go decisions using inexpensive in vitro tests. This innovative process will substantially save time and money in drug development and deliver breakthrough therapies that transform lives and reduce healthcare spending.